Pharmaceutical Management Agency

Future Procurement Opportunity (FPO) - Supply of Bevacizumab

Pharmac is planning on issuing a competitive process for supply of bevacizumab.

Bevacizumab is currently funded for recurrent respiratory papillomatosis, ocular neovascularisation and exudative ocular angiopathy in Health NZ Hospitals. The current eligibility criteria for bevacizumab can be found here: https://schedule.pharmac.govt.nz/HMLOnline.php?edition=&osq=bevacizumab

This competitive process may result in additional funded indications. It may, or may not, also result in widened access to the current criteria.

The Pharmaceutical Schedule is a list of funded medicines in the community and/or that can be used in Health New Zealand | Te Whatu Ora hospitals. More information on the Schedule can be found here: https://pharmac.govt.nz/pharmaceutical-schedule/about-the-schedule

Funding applications for bevacizumab currently under consideration can be found on the Pharmac Application Tracker (https://connect.pharmac.govt.nz/apptracker/s/global-search/Bevacizumab). Links to specific funding proposals under consideration are provided below.

Bevacizumab used in the treatment of hepatocellular carcinoma:
• Proposal: P-001618 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000AlzxU/p001618)

Bevacizumab used in the treatment of colorectal cancer:
• Proposal: P-000055 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptpo/p000055)

Bevacizumab used in the treatment of glioma:
• Proposal: P-000265 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptvh/p000265)
• Proposal: P-000740 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puCg/p000740)

Bevacizumab used in the treatment of ovarian cancer:
• Proposal: P-001366 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pufP/p001366)
• Proposal: P-001803 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BTk6R/p001803)

Bevacizumab used in the treatment of cervical cancer:
• Proposal: P-000311 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptxU/p000311)

Indicative RFx Release Date: Q3 2024
Project Status: Initial development
Indicative Total Value: $5M - $10M
Expected number of contracts offered: 1